All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2017-04-10T08:58:59.000Z

AACR 2017 | Primary results from the pivotal ZUMA-1 trial of KTE-C19 in refractory aggressive Non-Hodgkin Lymphoma patients

Apr 10, 2017
Share:

Bookmark this article

On Sunday 2nd April, during the “CTSY02 - Immuno-oncology Biomarkers in Clinical Trials” session at AACR 2017, Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, gave a talk titled “Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL).”

Dr. Locke began his talk by explaining that there is a significant unmet need in refractory aggressive Non-Hodgkin Lymphoma (NHL). It is the most common cancer of the blood in the United States and outcomes for refractory aggressive disease is poor: in the SCHOLAR-1 meta-analysis ORR was 26% (CR = 8%; PR = 18%) and median OS was 6.6 months.

Axicabtagene ciloleucel (axicel; KTE-C19) is an autologous, Chimeric Antigen Receptor (T-cell) therapy specific against CD19+ cells and functions via CD3ζ/CD28-based signaling.

Dr. Locke then discussed the design of the ZUMA-1 trial:

The talk then focused on the preliminary results of the trial, which met its primary endpoint of ORR (P < 0.0001) in the combined group. In addition to this, 44% of responses are ongoing after a median follow-up of 8.7 months.

Dr. Locke went on to state that 6-month PFS rates were consistent across key covariates. A median PFS of 5.9 months (95% CI, 3.4–9.8) was reported and median OS is not reached at the median follow-up of 8.7 months (95% CI, 10.5–NR). Compared with the SCHOLAR-1 data, 6-month OS rate is higher in the ZUMA-1 trial: 55% versus 80%, respectively.

An overview of adverse events experienced during the trial was presented:

Dr. Locke concluded the talk with a succinct summary slide, emphasizing that ZUMA-1 is the first pivotal trial of CD19-specific CAR T-cell therapy in patients with refractory aggressive NHL.

  1. Locke F.L. Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL) [Presentation]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Abstract nr [CT019].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
42 votes - 80 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox